{"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"1"},{"groupId":"OG001","value":"1"},{"groupId":"OG002","value":"9"}]}],"title":"Positive"},{"categories":[{"measurements":[{"groupId":"OG000","value":"9"},{"groupId":"OG001","value":"9"},{"groupId":"OG002","value":"0"}]}],"title":"Negative"},{"categories":[{"measurements":[{"groupId":"OG000","value":"0"},{"groupId":"OG001","value":"0"},{"groupId":"OG002","value":"1"}]}],"title":"Missing"},{"categories":[{"measurements":[{"groupId":"OG000","value":"0"},{"groupId":"OG001","value":"0"},{"groupId":"OG002","value":"0"}]}],"title":"Unclear"}],"denoms":[{"counts":[{"groupId":"OG000","value":"10"},{"groupId":"OG001","value":"10"},{"groupId":"OG002","value":"10"}],"units":"Participants"}],"description":"DCE-MRI, an FDA approved gadolinium chelate (e.g. Magnevist, Berlex Laboratories, NJ, USA) will be administered intravenously at 3 cc/sec using an automated pump injector (Medrad, Pittsburgh, PA, USA). The criteria was presence of early and diffuse hyper-enhancement compared to the surrounding bone marrow. The pattern of marrow involvement on MRI was characterized as: (1) normal when there was no evidence of abnormal signal intensity; (2) focal, which consisted of localized areas of abnormal marrow; the lesions are darker than yellow marrow and slightly darker than or isointense to red marrow on T1-weights images; (3) diffuse, in which normal bone marrow signal intensity is completely absent, the intervertebral disks appear brighter than or isointense to the diseased marrow; and finally (4) heterogeneous that consists of innumerable small foci of disease on a background of intact marrow, with small dark lesions on T1-weighted images, which become bright on T2-weighted image.","groups":[{"description":"MGUS (Monoclonal gammopathy of undetermined significance) is a premalignant plasma cell proliferative disorder.","id":"OG000","title":"MGUS (Monoclonal Gammopathy of Undetermined Significance)"},{"description":"Smoldering multiple myeloma (SMM)is a premalignant plasma cell proliferative disorder.","id":"OG001","title":"SMM (Smoldering Multiple Myeloma)"},{"description":"Multiple myeloma is a plasma cell neoplasm.","id":"OG002","title":"MM (Multiple Myeloma)"}],"paramType":"COUNT_OF_PARTICIPANTS","populationDescription":"Missing means the imaging test was not done. Unclear means it is indeterminate whether an imaging result is positive or negative.","reportingStatus":"POSTED","timeFrame":"60 days","title":"Count of Participants With Positive DCE-MRI Imaging Results","type":"PRIMARY","unitOfMeasure":"Participants"}